Aerocrine Provides Update on Insurance Coverage of FeNO

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 19, 2014 at 12:00 PM

Aerocrine Provides Update on Insurance Coverage of FeNO test in US.

SOLNA, Sweden - 19 March, 2014 - Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Care Service Corporation will begin covering FeNO testing for asthma diagnosis and management effective April 1, 2014. Aerocrine has received notification that Health Care Service Corporation (HCSC) will implement a positive coverage policy for Fractional exhaled Nitric Oxide (FeNO) testing for the diagnosis and management of asthma effective April 1, 2014. HCSC, the 5th largest private payer in the US, provides insurance coverage for 14 million individuals. HCSC subsidiaries include Blue Cross and Blue Shield plans of Illinois, Montana, New Mexico, Oklahoma, and Texas. The new HCSC policy is a positive coverage policy that states FeNO testing may be considered medically necessary for the diagnosis and treatment of asthma. This change in policy now allows reimbursement of claims based on medical necessity. In the last three years, several of the large Blue Cross and Blue Shield plans have altered their policies to begin paying for Aerocrine’s test. These include: WellPoint/Anthem Blue Cross Blue Shield, Blue Cross Blue Shield of Florida, Horizon Blue Cross and Blue Shield, Blue Cross and Blue Shield of Minnesota and Premera Blue Cross Blue Shield. Aerocrine’s test is now reimbursed by the three largest Blue Cross and Blue Shield companies in the United States, plans that account for over 40 million covered lives. In all, 64% of US insured lives now have access to Aerocrine’s test nationwide. HCSC, spent many months reviewing the latest information available and thoroughly challenged the clinical utility and outcomes information. This is a very positive change that we hope will encourage other payers to review their FeNO coverage policies and provide coverage,” said Scott Myers, CEO, Aerocrine AB “We believe this change at HCSC will demonstrate to physicians that insurers support FeNO testing to improve clinical decision making, patient and health economic outcomes for asthma management.” Insurance companies typically review their medical policies on an annual basis or whenever substantially new clinical information becomes available. Currently, seven of the US’s top 12 insurers provide coverage and reimbursement for this test. During the first quarter; CIGNA and Highmark, the fourth and eighth largest insurers respectively have maintained a non-coverage policy. FeNO testing is a two minute, objective, point-of-care breath test that can be used to identify patients with allergic airway inflammation. Airway inflammation is widely recognized as the underlying cause of asthma. Using routine FeNO testing to guide therapy, particularly inhaled corticosteroid therapy, for asthma patients has been shown to reduce asthma exacerbations up to 50 percent. “FeNO is an important addition to the management of many patients with asthma. It allows the presence of steroid responsive airway inflammation to be identified. FeNO testing helps clinicians prescribe the optimal medications and doses for their asthma patients which can improve patient outcomes,” said Dr. Neal Jain, MD, FAAAAI, FAAP. Aerocrine’s NIOX MINO® is the only FeNO device that is cleared by the FDA and commercially available in the United States. NIOX MINO is a simple device that delivers a numerical FeNO score during routine patient visit. Asthma is one of this world’s most common and costly diseases, affecting 8-10% of the population and costing more than $50B annually in the US alone. The disease has no cure and proper diagnosis and management of the disease are important to obtaining optimal control of a patient’s asthma. For more information regarding the change in the HCSC policy see the following link: http://medicalpolicy.hcsc.net/medicalpolicy/h...&TARGE T MED=PENDING&ctype=DESCRIPTION&pageSize=20&select=PENDING#hlink (Click on Pending Policies to the Left) For more information, contact: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788 379, +970 368 0336 Ken Marshall, Chief Marketing Officer and President Aerocrine, Inc. +919 280 9687 Dr. Kathy Rickard, Chief Medical Officer, Aerocrine AB +919 749 6708 About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU) Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 03/19/2014 at 4.45 p.m.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Centrus Energy's Quarter Ups and Downs Unpacked

Stirring the Pot: Centrus Energy's Rollercoaster Quarter Trading never fails to serve up surprises, and Centrus Energy Corp. (NYSE:LEU) is dishing them out this quarter. Despite a revenue slip to $55.5 million from last year’s $74.9 million, GAAP net income rocketed to a whopping $31.6 million. Talk about a mixed bag of fortunes. Diving Deeper into the Numbers Revenue...

Gates Unveils Poly Chain® Carbon™: A Game Changer?

Rethinking Industrial Chains with Poly Chain® Carbon ONE Amid today's relentless industrial landscape, Gates Industrial Corporation is stepping into the spotlight by debuting the Poly Chain® Carbon™ ONE. This ain't just another product release—it's a full-throttle attempt to shake up the heavy-duty power transmission industry. Stakeholders, take note: this launch...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

Belay Diagnostics Clinches Second Palantir Title

Innovation in Liquid Biopsy Lands Belay Another Win Another round of applause is due for Belay Diagnostics, the brainy bunch in molecular diagnostics focused on CSF liquid biopsy for CNS cancers. This Chicago-based powerhouse clinched its second consecutive victory at the Palantir Foundry Buildcamp competition. The team must be on some winning streak, as they're not just...

Life with PAH: A Journey of Awareness and Hope

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Menarini & Ryvu's Phase II Results Offer Hope in B-NHL

New Glimmers of Hope in B-cell NHL Battle Battling aggressive B-cell non-Hodgkin lymphoma (B-NHL) isn't for the faint of heart, especially when standard treatments have been run through like an old pair of boots. Enter dapolsertib, the fresh-faced newcomer in Menarini Group and Ryvu Therapeutics' arsenal, showing encouraging signals in early Phase II results. These...

Peabody's Q3 2026: Margins Climb Despite Net Loss

Tough Quarters but Promising Margins Alright, Peabody's Q3 2026 isn't the most sunshine-filled report I've laid eyes on, but it's not all shadows either. Sure, they posted a net loss of $32.8 million, better than last year's $70.1 million drain. Admit it or not, that's improvement. And yet, the real gem here is those expanding margins gleaming despite the loss-heavy...

Kaolin Market Surges to $8.89B by 2031: Key Trends

Riding the Kaolin Wave: Industrial Market Expansion You can't miss the sound of kaolin clinking in as it rides the tide of industrial demand. Reports from MarketsandMarkets™ have kaolin's party rocking all the way to a hefty $8.89 billion by 2031, up from $6.19 billion in 2026. With a sensible 7.5% compound annual growth rate (CAGR), this clay’s is aiming for the...

What's the Deal with Generations+ at P.C. Richard & Son? Felt like companies were giving away the farm just to keep customers hooked, and then I heard about P.C. Richard & Son's latest play. They've been around for a scorching 117 years, and now they're offering something they've never done before: a free membership program called Generations+ that tosses perks like candy...

AlphaESS Stretches Influence with Adriatic Energy Boost

AlphaESS Charges into the Adriatic Region Kicking off with a bang in Zagreb, AlphaESS didn't just show up at the Green Energy Fair 2026—they turned the spotlights on their expanding role across the Adriatic region. This ain't your run-of-the-mill industry showcase. They've been busy throwing up energy storage units like they're growing crops. With a strong lineup...